Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization’ and are disseminating deceptive marketing that put patient safety at risk.” Novo Nordisk further stated “the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies” may contain “unsafe and illicit foreign ingredients.”

On this news, Hims’ stock price fell as much as 32% during intraday trading on June 23, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Hims securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith

3070 Bristol Pike, Suite 112

Bensalem, Pennsylvania 19020

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com

Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623811981/en/